Latest Regeneron News & Updates

See the latest news and media coverage for Regeneron. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Regeneron

Biopharmaceutical company

regeneron.com
Headquarters
Tarrytown, United States
Company type
Public company
Number of employees
15,000+

Last updated

Latest news about Regeneron

In short: Regeneron reported a 19% revenue increase for Q1 2026 and achieved significant FDA approvals for its Dupixent and Otarmeni therapies.

Company announcements

  • Regeneron

    Regeneron announces Dupixent improves esophageal function in EoE trial

    Phase 4 REMODEL trial shows significant improvements in distensibility, structural changes, and inflammation at week 24 versus placebo. Results presented at DDW 2026.

  • Regeneron

    Regeneron reports Q1 2026 financial results

    Revenues rise 19% to $3.6B. Several approvals including EYLEA HD, Dupixent, Otarmeni. New $3B share repurchase authorized.

  • Regeneron

    Regeneron publishes paper on myostatin variants

    Variants preserve muscle mass during weight loss, increase skeletal muscle, reduce fat without cardiac risks. Discovery aids weight management.

  • Regeneron

    Regeneron announces new 2030 responsibility goals

    Goals focus on science innovation, medicine access, STEM education, internal promotions, renewable energy, and zero waste-to-landfill. They surpassed 2025 targets amid business growth.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Regeneron

Track Regeneron and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Regeneron competitors & trending companies

Browse news for competitors to Regeneron and other trending companies.